Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
73.44
+0.49 (0.67%)
Oct 14, 2025, 3:25 PM EDT - Market open
Edwards Lifesciences Revenue
Edwards Lifesciences had revenue of $1.53B in the quarter ending June 30, 2025, with 11.89% growth. This brings the company's revenue in the last twelve months to $5.69B, up 9.14% year-over-year. In the year 2024, Edwards Lifesciences had annual revenue of $5.44B with 8.57% growth.
Revenue (ttm)
$5.69B
Revenue Growth
+9.14%
P/S Ratio
7.57
Revenue / Employee
$359,816
Employees
15,800
Market Cap
43.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.44B | 429.50M | 8.57% |
| Dec 31, 2023 | 5.01B | 546.00M | 12.23% |
| Dec 31, 2022 | 4.46B | -768.50M | -14.69% |
| Dec 31, 2021 | 5.23B | 846.20M | 19.29% |
| Dec 31, 2020 | 4.39B | 38.30M | 0.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
EW News
- 2 days ago - Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation - EW - PRNewsWire
- 3 days ago - EW Investor News: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW - GlobeNewsWire
- 19 days ago - EW Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW - Business Wire
- 6 weeks ago - Updated ESC/EACTS Guidelines Mark Advancement in Structural Heart Disease Care - Business Wire
- 7 weeks ago - Edwards Lifesciences Announces $500 Million Accelerated Share Repurchase - Business Wire
- 2 months ago - Edwards Lifesciences Corporation Investors: Company Investigated by the Portnoy Law Firm - GlobeNewsWire
- 2 months ago - Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025 - Seeking Alpha
- 2 months ago - JenaValve Responds to FTC's Action Against Proposed Edwards Lifesciences Acquisition - GlobeNewsWire